Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $415 from $408 and keeps an Overweight rating on the shares following the approval of Casgevy. Both label and pricing appear favorable for commercial uptake for Casgevy given the black-box warning and stringent monitoring requirements for Bluebird’s (BLUE) Lyfgenia, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex (NASDAQ:VRTX), CRISPR Therapeutics Slip despite Sickle Cell Treatment Approval
- Crispr says Casgevy approval triggers $200M milestone payment
- Vertex sets $2.2M as U.S. wholesale acquisition cost for Casgevy
- Vertex and Crispr announce FDA approval of Casgevy for sickle cell disease
- Mizuho sees black box warning just for Bluebird, not Crispr